Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Organisation › Details

Orphazyme A/S (Nasdaq Copenhagen: ORPHA.CO)

Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins and lysosomal dysfunction. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). *

 

Period Start 2009-06-01 established
  Group Orphazyme (Group)
  Predecessor Orphazyme ApS
Products Industry enzyme replacement therapeutic
  Industry 2 DRUGS, ORPHAN
Persons Person Stratton, Kim (Centogene 202202– CEO before Orphazyme + Shire Pharmaceuticals + Novartis)
  Person 2 Vadsholt, Anders (TopoTarget 201011 CFO)
     
Region Region København (Copenhagen)
  Country Denmark
  Street 3 Ole Maaløes Vej
  City 2200 Copenhagen N
  Tel +45-39-178272
    Address record changed: 2024-01-05
     
Basic data Employees n. a.
     
    * Document for »About Section«: Centogene AG. (5/9/18). "Press Release: Centogene Announces Drug Development Collaboration with Orphazyme in Neuronopathic Gaucher Disease". Rostock.
     
   
Record changed: 2024-02-12

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Orphazyme (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px




» top